Cervical cancer is a cancer that develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. Alfa Cytology is a world leader in the research of gynecologic cancer. With our extensive experience and advanced platform, we can provide the best solutions for cervical cancer.
Introduction to Cervical Cancer
Cervical cancer is one of the most common types of cancer affecting women worldwide. In the United States, there are over 13,000 new cases diagnosed each year. Human papillomavirus (HPV) infection is an important risk factor for its development, specifically HPV-16 and HPV-18. However, genetic and lifestyle factors may also increase the risk. There are three most common types of cervical cancer. Squamous cell carcinoma, which forms in the lining of the cervix, is the most common type of cervical cancer. Adenocarcinoma, which forms in cells that produce mucus. Mixed carcinoma, both squamous cell carcinoma and adenocarcinoma features.
Fig.1 The four stages of cervical cancer.
Therapy for Cervical Cancer
The study of cancer epitopes and targets of cervical cancer is essential for the development of targeted therapies and immunotherapies. Specific antigens expressed on cervical cancer cells can be targeted as therapeutic strategies, including HPV cancer proteins and immune checkpoints.
HPV vaccination
The HPV vaccine plays an important role in preventing HPV infection and reducing the risk of cervical cancer and other HPV-related cancers. HPV vaccines such as Gardasil and Cervarix are preventive measures that target high-risk HPV strains linked to cervical cancer.
Novel therapies
Novel therapies including immunotherapies, targeted drugs, and combination therapies are being investigated to improve outcomes with advanced or recurrent cervical cancer. Checkpoint inhibitors like pembrolizumab and nivolumab are being studied for their role in enhancing the immune response against cervical cancer cells.
Gene therapy
Genetic studies help identify genetic mutations and biomarkers associated with the development and progression of cervical cancer. It may help personalize therapy approaches and predict responses to specific therapies.
Our Services
Cervical cancer is a major health problem for women around the world. Therefore, Alfa Cytology is working on providing one-stop solutions for cervical cancer, including but not limited to the following.
Models of Cervical Cancer
Alfa Cytology specializes in providing various animal models tailored for cervical cancer research. These models are valuable tools to study cervical cancer etiology, progression, and therapy. By different model types and optional species, it is possible to gain a deeper understanding of this prevalent gynecological malignancy and develop innovative therapy strategies.
| Transplantable Models |
Transgenic Models |
Transplantable models involve the transplantation of cervical cancer cells or tissues into experimental animals, facilitating the examination of tumor growth, metastasis, and the evaluation of therapeutic interventions. Our selection of transplantable models includes the following.
|
Transgenic models are genetically modified animals that simulate specific genetic alterations associated with ocular melanoma. These models are helpful to study the effects of targeted genetic mutations and explore the underlying disease mechanisms.
- HPV Transgenic Models
- P53 Knockout Models
- Notch Pathway Altered Models
|
Alfa Cytology also offers a range of animal model options specifically designed for cervical cancer research, the species include mice, rats, zebrafish, chicks, dogs, non-human primates, and others.
Alfa Cytology is committed to the research and study of cancer, from cell therapy development services, and immune checkpoint inhibitor development services, to cancer drug development services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for cervical cancer. If you are interested in our service, please contact us.
For research use only.
Related Services
